Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent split-virion influenza vaccine (Shenzhen Kangtai Biological Products)
- Development stage
- Preclinical
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 4-valent influenza vaccine (split) is a quadrivalent split-virion vaccine candidate being developed by Shenzhen Kangtai Biological Products (Shenzhen Kangde) for the prevention of seasonal influenza. As a quadrivalent vaccine, it is designed to provide broader protection than traditional trivalent vaccines by including antigens from four different influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and two influenza B lineages (typically Victoria and Yamagata). The split-virion technology involves disrupting the virus with detergents to expose internal and surface antigens, which generally results in a vaccine that is highly immunogenic while maintaining a favorable safety profile. The candidate is currently in the preclinical/R&D stage of development.
- Other names
- 4-valent influenza vaccine4-Valent Influenza Vaccine (split)Quadrivalent Influenza VaccineQuadrivalent split-virion influenza vaccine
02
Targets
HA (Influenza virus hemagglutinin (quadrivalent))Neuraminidase
Beyond the preview
Go deeper on quadrivalent split-virion influenza vaccine (Shenzhen Kangtai Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent split-virion influenza vaccine (Shenzhen Kangtai Biological Products).